DSG1 and acquired polycythemia vera: Our finding that PV patients who lack response to rituximab fail to reduce both IgG1 and IgG4 anti-Dsg1 antibodies further supports the pathogenicity of both subclasses and the greater prognostic value of a fall in anti-Dsg1 versus anti-Dsg3 antibodies.